Abstract
Background The currently available medications for treating membranous nephropathy (MN) still have unsatisfactory efficacy in inhibiting disease recurrence, slowing down its progression, and even halting the development of end-stage renal disease. There is still a need to develop novel drugs targeting MN.
Methods We utilized summary statistics of MN from the Kiryluk Lab and obtained plasma proteins from Zheng et al., Decode, and UKBioBank and gene data from eQTLgen and GTEX. We performed a two-sample Bidirectional mediation Mendelian randomization analysis, SMR analysis, HEIDI test, Bayesian colocalization, phenotype scanning, external validation, mediation analysis, drug bank analysis, and protein-protein interaction network.
Results The Mendelian randomization analysis uncovered 8 distinct proteins associated with MN after False Discovery Rate multiple correction. Proteins associated with an increased risk of MN in plasma include ABO [(Histo-Blood Group Abo System Transferase) (WR OR = 1.116, 95%CI:1.047-1.190, FDR=0.090, PPH4 = 0.795)], VWF [(Von Willebrand Factor) (WR OR = 1.412, 95%CI:1.157-1.725, FDR=0.018, PPH4 = 0.816)] and CD209 [(Cd209 Antigen) (WR OR = 1.187, 95%CI:1.074-1.312, FDR=0.090, PPH4 = 0.795)], and proteins that have a protective effect on MN: HRG [(Histidine-Rich Glycoprotein) (WR OR = 1.814, 95%CI:1.345-2.445, FDR=0.018, PPH4 = 0.797)], CD27 [(Cd27 Antigen) (WR OR = 0.785, 95%CI:0.681-0.904, FDR=0.018, PPH4 = 0.797)], LRPPRC [(Leucine-Rich Ppr Motif-Containing Protein, Mitochondrial) (WR OR = 0.790, 95%CI:0.688-0.907, FDR=0.090, PPH4 = 0.797)], TIMP4 [(Cd27 Antigen) (WR OR = 0.666, 95%CI:0.527-0.840, FDR=0.090PPH4 = 0.833)] and MAP2K4 [(Metalloproteinase Inhibitor 4) (WR OR = 0.815, 95%CI:0.723-0.919, FDR=0.090, PPH4 = 0.797)]. None of these proteins exhibited a reverse causal relationship. Bayesian colocalization analysis provided evidence that all of them share variants with MN. In external validation, ABO, CD27, HRG, MAP2K4, TIMP4, and VWF showed significant mediation results. We identified type 1 diabetes, trunk fat, and asthma as having intermediate effects in these pathways. We discovered several genes that are causally related to MN.
Conclusions Our comprehensive analysis indicates a causal effect of ABO, CD209, CD27, HRG, LRPPRC, MAP2K4, and TIMP4 at the genetically determined circulating levels on the risk of MN. These proteins have the potential to be a promising therapeutic target for the treatment of MN. We identified type 1 diabetes, trunk fat, and asthma as having intermediate effects in these pathways. We discovered several genes that are causally related to MN.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: Shenzhen Key Medical Discipline Construction Fund (SZXK009).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used for analysis in this study are publicly available, and we can download them from relevant articles for analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This article used three proteomic databases for SMR analysis and HEIDI testing, and added mediating factor analysis. Gene data from eQTLgen and GTEX were used for SMR analysis and HEIDI testing. Figure 1 was updated, and the remaining figures were deleted. Other data will be presented in table form.
